The Patent Finder

Salt of Pyrrolo[2,3-d]pyrimidine Compound and Novel Polymorph of Salt

Crystal Pharmatech Co., Ltd.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 10,138,250Salt of Pyrrolo[2,3-d]pyrimidine Compound and Novel Polymorph of Salt
In force
 · High confidence
Crystal Pharmatech Co., Ltd.In force
High confidence
US 9,994,579Salt of Pyrrolo[2,3-d]pyrimidine Compound and Novel Polymorph of Salt
Lapsed Jun 12, 2026 on the fee record
Ended Jun 12, 2026 · High confidence
Crystal Pharmatech Co., Ltd.Lapsed Jun 12, 2026 on the fee recordEnded Jun 12, 2026
High confidence
2 of 2 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Crystal Pharmatech Co., Ltd..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited